Navigation Links
Vitamin A derivative associated with reduced growth in some lung cells
Date:10/30/2007

Treatment with a derivative of vitamin A called retinoic acid was associated with reduced lung cell growth in a group of former heavy smokers, according to a study published online October 30 in the Journal of the National Cancer Institute.

Former smokers remain at elevated risk for lung cancer. According to one hypothesis, lung cells that were damaged during years of smoking may continue to grow and evolve into cancer even after that person has quit smoking. Previous studies have suggested that retinoids, a class of drugs related to vitamin A, may be effective for preventing lung cancer in former smokers. Retinoids have also been shown to slow the growth of cancer cells in laboratory experiments.

Investigators at the University of Texas M.D. Anderson Cancer Center in Houston previously conducted a double-blind lung cancer prevention trial among 225 former heavy smokers. The subjects were randomly assigned to receive a 3-month treatment of 13-cis-retinoic acid and vitamin E, or 9-cis-retinoic acid, or a placebo. Walter Hittelman, Ph.D., and colleagues later examined biopsy samples of participants lung tissue taken before and after treatment, then measured the proliferation of the cells using a biomarker called Ki-67.

Both treatments reduced cell proliferation in one layer of the lung cells (the parabasal layer), but not the other (the basal layer), which surprised the researchers.

In patients given 13-cis-retinoic acid and vitamin E, there was a statistically significant reduction in parabasal layer cell growth compared with the placebo treatment, but not in those given 9-cis-retinoic acid. When the data were analyzed by the biopsy site, both treatments statistically significantly reduced cell growth.

It will therefore be important to distinguish the effects of molecularly targeted agents on the basal and parabasal [lung cell] layers in proposed lung chemoprevention trials with long follow-up, the authors write.

In an accompanying editorial, Eva Szabo, M.D., of the National Cancer Institute in Bethesda, Md., discusses the appropriateness of using the biomarker Ki-67 as an alternative endpoint in cancer prevention trials. While the biomarker showed that the retinoid agents were able to reduce cell growth, she says it is still too soon to test them in more advanced clinical trials. We do not have a full understanding of the effects of these agents on [lung cells] or their effects during the full spectrum of carcinogenesis, she writes.


'/>"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Vitamin B12 can help in detecting cancers
2. Vitamins-The answer to Heart Disease?
3. Vitamin E, the latest warrior against diabetes
4. Vitamin Shields Brittle Bones
5. Beer vitamin protects heart
6. B Vitamin protects and lowers toxicity of Arthritis Drug
7. B Vitamin Supplementatoin Saves Money and Lives
8. Eat Vitamin C and stay young
9. Taking Vitamin Supplements With Caution
10. Vitamin C reverses pre eclampsia
11. Bony Vitamin D a boon for lungs too
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 25, 2017 , ... The doctors at Wall Centre Dental are now expanding ... and require sedation to receive dental care. The doctors offer three treatment options to ... cleanings to oral surgery, at their dental office in Vancouver. Wall Centre Dental is ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... 25, 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis ... –can’t help but be heartened by the industry’s current surge. But another thing that ... “skunk smell.” At last they can simply, safely and effectively end their aroma ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine ... Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, ... of Arizona College of Medicine. He also serves as Medical Director for the Bureau ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... instrument solutions, announces the continuation of its strategic partnership with and platinum sponsorship ... developing nations in the safe and effective management of complex spine deformity cases, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
Breaking Medicine Technology: